Peijia Medical announced financial results for the six months ended June 30, 2025 on August 22, 2025.
The Group reported sustained revenue growth and significantly improved expense ratios, driving a structural enhancement in profitability. Revenue reached RMB353.4 million, up 17.3% period-to-period.
Revenue composition remained stable, with TAVR related products and neurointerventional products accounting for 45.7% and 54.3%, respectively. Revenue from TAVR-related products increased 24.0% to RMB161.6 million, fueled by market share gains in China’s transfemoral TAVR market and a favorable product mix shift toward newer premium products. Neurointerventional product revenue grew 12.2% to RMB191.8 million, supported by deeper penetration of key products and the successful launch of the YonFlow® Flow Diverting Stent.
Lean management and operational optimization significantly improved expense ratios across both business segments. Most notably, the Transcatheter Valve Therapeutic Business achieved commercial profit for the first time, representing a major milestone in our path to structural profitability. The Neurointerventional Business continued to deliver profit expansion amid mature growth.
With three core products in the final registration stage and multiple breakthrough technologies advancing globally, Peijia are well-positioned for sustained future growth.
For more information, please visit: https://en.prnasia.com/global_releases/industry_BIO.shtml
